ERBB2 and breast cancer: The correlation of SIPL1 expression with poor survival for patients with PR+ or ER+ breast cancer does not exclude the possible contributions of SIPL1 to the tumorigenesis of HER2+ and triple negative breast cancer, as gain of the SIPL1 gene and increases in the SIPL1 mRNA were demonstrated in these BC types in comparison with normal breast tissues.